Jeffrey Kopp, MD
Entry Id: TP-723

Overview
The Kidney Disease Section is located in the National Institute of Diabetes and Digestive and Kidney Disease and conducts basic and clinical research into the pathophysiology and treatment glomerular diseases.

Structure of the Training Program
A position is available for an individual to be appointed as a Senior Clinical Research Fellow. Applications will be considered from individuals who have completed an AGME-certified nephrology training program and have a US medical license. The duration of the fellowship is typically 2-5 years. Individuals may be hired under Civil Service regulations or may be offered a commission in the US Public Health Service. Candidates with educational loans may be eligible for the NIH Loan Repayment Program.

Physicians in the KDS may choose to learn to how to conduct high-quality, translational clinical studies in adult patients with various glomerular diseases. To this end, fellows will enroll in the NIH-Duke Clinical Research Training Program, which involves two years of class-work in epidemiology, statistics, and trial design and leads to a Master of Health Sciences degree.

Opportunities are also available in basic research into the pathogenesis of glomerular disease, with a focus on podocytopathies.

• James E. Balow, MD: Lupus nephritis, immunologic renal disease
• Howard A. Austin, III, MD: Lupus nephritis, membranous nephropathy
• Jeffrey B. Kopp, MD: Focal segmental glomerulosclerosis, HIV-associated kidney disease
• Monique Cho, MD: Diabetic nephropathy, sickle cell kidney disease

Examples of Recent Papers Authored by Program Faculty

• Kitiyakara C, Eggers P, Kopp JB. Twenty-one year trend in end-stage renal disease due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44:815-825, 2005.
• Zaragoza C, Li R-M, Fahle, GA, Fischer SH, Raffeld M, Lewis AM, Kopp JB. Squirrel monkeys support replication of BK virus more efficiently that SV40: an animal model for human BK virus infection. J Virology 79:1320-1326, 2005.
• Orloff MS, Iyengar SK, Winkler CA, Goddard KAB, Dart RA, Ahuja TS, Mokryzcki M, Briggs, WA, Korbet SM, Kimmel PL, Simon EE, Trachtman H, Vlahov D, Michel DM, Berns JS, Smith MC, Schelling JR, Sedor JR, Kopp JB. Variants in the Wilms tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 14:212-221, 2005.
• Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y, Austin H, Tisdale J, Barrett J, Geller N, Childs R. Nephrotic syndrome: an under-recognized immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol. 131:74-9, 2005.
• Monkawa T, Pippin J, Yo Y, Kopp JB, Alpers CE, Shankland SJ. The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 102:e8-18, 2006.
• Balasubramanyam A, Mersmann H, Jahoor F, Phillips T, Schubert U, Brar B, Iyer D, Smith EO, Takahashi H, Lu H, Kopp JB. Effects of transgenic expression of HIV-1 protein Vpr on energy metabolism in mice. Am J Physiol, 242:E40-48, 2007.
• Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF, Chitkara P, Fleisher T, Klippel JH, Balow JE, Boumpas DT. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
  Rheumatology (Oxford). 46:952-6, 2007.
• Xu Q, Norman JT, Shrivastav S, Lucio-Cazana J, Kopp JB. Cell-based models of TGF-b induced fibrogenesis for high-throughput screening of anti-fibrotic agents. Am J Physiol, in press.
• Cho M, Hurley J, Kopp JB. Sirolimus therapy for focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis, 49:310-7, 2007.
• Cho M, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slow renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol, in press.

Apply here, or send curriculum vitae and cover letter to the contact information to the right.

The NIH is dedicated to building a diverse community in its training and employment programs.